Long-term evaluation of infliximab in the treatment of persistently active Juvenile Idiopathic Arthritis refractory to conventional therapy;Valutazione a lungo termine di infliximab nel trattamento dell'artrite idiopatica giovanile persistentemente attiva e refrattaria alle terapie convenzionali

Reumatismo

Volumn 59, Issue 1, 2007, Pages 50-56

  de Marco, Gabriele ^a   Gerloni, V ^a   Pontikaki, I ^a   Lurati, A ^a   Teruzzi, B ^a   Salmaso, A ^a   Valcamonica, E ^a   Gattinara, M ^a   Fantini, F ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

DMARDs refractory; Infliximab efficacy; Juvenile Idiopathic Arthritis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DNA ANTIBODY; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ANXIETY; ARTHRALGIA; ARTICLE; CHILD; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE EXACERBATION; DRUG CHOICE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAM; FATIGUE; FEMALE; FLUSHING; HEART PALPITATION; HUMAN; HYPOTENSION; JUVENILE RHEUMATOID ARTHRITIS; LARYNX EDEMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; OPEN STUDY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; THORAX PAIN; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULIN TEST; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; INTRAVENOUS DRUG ADMINISTRATION; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHOTREXATE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34447261199     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 1998; 25: 1991-4.
2. Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis: why does it vary so much? J Rheumatol 2002; 29: 1520-30.
3. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 1992; 326: 1043-9.
4. Van Rossum MA, Fiselier TJ, Franssen MJ, Zwinderman AH, ten Cate R, van Suijlekom-Smit LW, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998; 41: 808-16.
5. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342: 763-9.
6. Ranza R, Marchesoni A, Calori G, Bianchi G, Braga M, Canazza S, et al. The italian version of the functional disability index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol 1993; 11: 123-8.
7. Ruperto N, Ravelli A, Pistorio A, Malattia C, Viola S, Cavuto S, et al. Paediatric Rheumatology International Trials Organisation. The Italian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001; 19(4 Suppl 23): S91-5.
8. Felson DT, Anderson JJ, BoersM, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
9. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
10. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (cA2) versus placebo in Rheumatoid Arthritis. Lancet 1994; 344: 1105-10.
11. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of Rheumatoid Arthritis. N Engl J Med 2000; 343: 1594-601.
12. Havell EA. Evidence that tumour necrosis factor has an important role in a antibacterial resistance. J Immunol 1989; 143: 2894-9.
13. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, et al. Mice deficient for the 55 kd tumour necrosis factor receptor are resistant to endotoxic shock, yet succumb to L monocytogenes infection. Cell 1993; 73: 457-67.
14. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
15. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999; 5: 119-33.
16. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumor necrosis factor a (cA2) in patients with Rheumatoid Arthritis. Lancet 1994; 344: 1125-6.
17. Favalli EG, Sinigaglia L, VarennaM, Arnoldi C. Druginduced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 2002; 11: 753-5.